LRP5 Antikörper (Internal Region)
-
- Target Alle LRP5 Antikörper anzeigen
- LRP5 (Low Density Lipoprotein Receptor-Related Protein 5 (LRP5))
-
Bindungsspezifität
- Internal Region
-
Reaktivität
- Human
-
Wirt
- Ziege
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser LRP5 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
- Verwendungszweck
- LRP5
- Sequenz
- ERVEKTTGDK RT
- Kreuzreaktivität
- Human, Maus, Ratte
- Aufreinigung
- Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
- Güteklasse
- Verified
- Immunogen
- Peptide with sequence C-ERVEKTTGDKRT, from the internal region of the protein sequence according to NP_002326.2.
- Isotyp
- IgG
- Top Product
- Discover our top product LRP5 Primärantikörper
-
-
- Applikationshinweise
-
Immunohistochemistry: In paraffin embedded Human Liver shows weak cytoplasm staining in some hepatocytes. Recommended concentration: 2-4 μg/mL.
Western Blot: Approx 180 kDa band observed in lysates of cell line HepG2 (calculated MW of 179 kDa according to NP_002326.2). Recommended concentration: 1-3 μg/mL. Primary incubation was 1 hour. Preliminary testing was unsuccessful on Mouse Liver for this p
Peptide ELISA: antibody detection limit dilution 1:16000.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 0.5 mg/mL
- Buffer
- Supplied at 0.5 mg/mL in Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handhabung
- Minimize freezing and thawing.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Aliquot and store at -20°C, with minimal freeze/thawing. A working aliquot may be refrigerated at 4°C for a few weeks and still remain viable.
-
-
MicroRNA-23a-3p inhibitor decreases osteonecrosis incidence in a rat model." in: Molecular medicine reports, Vol. 16, Issue 6, pp. 9331-9336, (2018) (PubMed).
: "
-
MicroRNA-23a-3p inhibitor decreases osteonecrosis incidence in a rat model." in: Molecular medicine reports, Vol. 16, Issue 6, pp. 9331-9336, (2018) (PubMed).
-
- Target
- LRP5 (Low Density Lipoprotein Receptor-Related Protein 5 (LRP5))
- Andere Bezeichnung
- LRP5 (LRP5 Produkte)
- Synonyme
- Xlrp5 antikoerper, bmnd1 antikoerper, evr1 antikoerper, evr4 antikoerper, hbm antikoerper, lr3 antikoerper, lrp5-A antikoerper, lrp7 antikoerper, oppg antikoerper, ops antikoerper, opta1 antikoerper, vbch2 antikoerper, LRP5 antikoerper, LRP6 antikoerper, BMND1 antikoerper, EVR1 antikoerper, EVR4 antikoerper, HBM antikoerper, LR3 antikoerper, LRP7 antikoerper, OPPG antikoerper, OPS antikoerper, OPTA1 antikoerper, VBCH2 antikoerper, mKIAA4142 antikoerper, low-density lipoprotein receptor-related protein 5 antikoerper, LDL receptor related protein 5 antikoerper, LDL receptor related protein 5 L homeolog antikoerper, low density lipoprotein receptor-related protein 5 antikoerper, LDL receptor related protein 5 like antikoerper, LOC100147353 antikoerper, LRP5 antikoerper, lrp5.L antikoerper, lrp5 antikoerper, Lrp5 antikoerper, LRP5L antikoerper
- Hintergrund
- LRP5, low density lipoprotein receptor-related protein 5, HGNC:6697, BMND1, HBM, LR3, LRP7, OPPG, OPS, VBCH2, low density lipoprotein receptor-related protein 7, osteoporosis pseudoglioma syndrome, EVR1, EVR4, OPTA1, exudative vitreoretinopathy 1,
- Gen-ID
- 4041
- NCBI Accession
- NP_002326
- Pathways
- WNT Signalweg, Stem Cell Maintenance, Positive Regulation of fat Cell Differentiation
-